Whole Genome Sequencing of Triple Negative Breast Cancer Reveals Previously
Study demonstrates power and potential of next generation sequencing for
CARLSBAD, Calif., Dec. 6, 2012
CARLSBAD, Calif., Dec. 6, 2012 /PRNewswire/ -- Whole genome sequencing has
revealed previously unreported mutations in metastatic triple-negative breast
cancer (TNBC), according to a study published by the journal Molecular Cancer
The study, "Genome and transcriptome sequencing in prospective triple negative
breast cancer uncovers therapeutic vulnerabilities," was sponsored by the
Translational Genomics Research Institute (TGen) and US Oncology Research with
support fromLife Technologies Corporation (NASDAQ: LIFE) and is currently
"The study underscores the potential clinical utility of genomic sequencing to
improve cancer care," said Paul Billings, M.D., Ph.D., chief medical officer
at Life Technologies. "Our hope is that in the not too distant future,
sequencing will become available to many more patients and physicians."
In a sample of 14 tumors from ethnically diverse metastatic TNBC patients, the
researchers found significant mutations and other changes in more than a dozen
genes through whole-genome sequencing performed on Life Technologies' Applied
Biosystems SOLiD™ 4.0 platform. The most frequently mutated gene among the
tumors (seven of 14) was the TP53 tumor suppressor, and aberrations were
observed in additional tumor suppressor genes including CTNNA1, which was
detected in two of six African-American patients (who typically have more
aggressive and treatment-resistant disease). Alterations were also seen in the
ERBB4 gene, known to be involved in mammary-gland maturation during pregnancy
and lactation, but not previously linked to metastatic TNBC.
The study included an "outlier analysis," which assessed expression patterns
for each tumor when compared against the other tumors examined in the study.
Specific cancer genes overexpressed among tumors in the study's cohort
included: ALK, AR, ARAF, BRAF, FGFR2, GLI1, GLI2, HRAS, HSP90AA1, KRAS, MET,
NOTCH2, NOTCH3, and SHH. Significantly underexpressed cancer genes included:
BRCA1, BRCA2, CDKN2A, CTNNA1, DKK1, FBXW7, NF1, PTEN, and SFN.
Each tumor was genomically unique, but nine of the 14 contained alterations in
one or both of two particular cellular pathways: RAS/RAF/MEK/ERK and
"Genome sequencing will eventually become a standard tool for oncologists,"
said Billings, "allowing them to tailor therapies to the unique genetic
profiles of each of their patients."
Metastatic TNBC is a highly aggressive form of breast cancer that
disproportionately affects African-Americans. It is called triple-negative
because tumors do not express the estrogen receptor, progesterone receptor or
HER-2, the biomarkers successfully targeted in most breast cancers.
Metastatic TNBC also has a poor prognosis once the cancer has spread to other
organs, with a median survival rate among metastatic patients of only one
year. While TNBC accounts for only about 15 percent of all breast cancers, its
more aggressive biology makes it responsible for nearly one in four deaths
related to this disease.
The SOLiD™ 4.0 is For Research Use Only. Not for use in diagnostic procedures.
Life Technologies Corporation(NASDAQ: LIFE) is a global biotechnology company
with customers in more than 160 countries using its innovative solutions to
solve some of today's most difficult scientific challenges. Quality and
innovation are accessible to every lab with its reliable and easy-to-use
solutions spanning the biological spectrum with more than 50,000 products for
agricultural biotechnology, translational research, molecular medicine and
diagnostics, stem cell-based therapies, forensics, food safety and animal
health. Its systems, reagents and consumables represent some of the most cited
brands in scientific research including: Ion Torrent™, Applied Biosystems®,
Invitrogen™, GIBCO®, Ambion®, Molecular Probes®, Novex®, and TaqMan®.Life
Technologiesemploys approximately 10,400 people and upholds its ongoing
commitment to innovation with more than 4,000 patents and exclusive licenses.
LIFE had sales of$3.7 billionin 2011. Visit us at our
Life Technologies'Safe Harbor Statement
This press release includes forward-looking statements aboutLife
Technologies'anticipated results that involve risks and uncertainties. Some
of the information contained in this press release, including, but not limited
to, statements as to industry trends andLife Technologies'plans, objectives,
expectations and strategy for its business, contains forward-looking
statements that are subject to risks and uncertainties that could cause actual
results or events to differ materially from those expressed or implied by such
forward-looking statements. Any statements that are not statements of
historical fact are forward-looking statements. When used, the words
"believe," "plan," "intend," "anticipate," "target," "estimate," "expect" and
the like, and/or future tense or conditional constructions ("will," "may,"
"could," "should," etc.), or similar expressions, identify certain of these
forward-looking statements. Important factors which could cause actual results
to differ materially from those in the forward-looking statements are detailed
in filings made byLife Technologies with theSecurities and Exchange
Commission.Life Technologies undertakes no obligation to update or revise any
such forward-looking statements to reflect subsequent events or circumstances.
Senior Manager, Public Relations for Regulated Markets
SOURCE Life Technologies Corporation
Press spacebar to pause and continue. Press esc to stop.